Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/14/2026, 12:00:00 AM
On April 14, 2026, the U.S. FDA refused to file partner Replimune's application for RP1 in combination with Opdivo for advanced melanoma due to study design concerns.
Korean Translation
2026년 4월 14일, 미국 FDA가 연구 설계 우려를 이유로 옵디보와 병용하는 리플리뮨의 진행성 흑색종 치료제 RP1 허가 신청 접수를 거부함.
Related Recent Events
Cloudflare Inc (NET) · Other
Cloudflare is scheduled to host an Investor Day on June 9, 2026; a >=5% price impact is estimated as the company provides strategic updates scheduled.
6/9/2026, 12:00:00 AM
Chipotle Mexican Grill Inc (CMG) · Other
Shareholders approved a 50-for-1 stock split at the annual meeting on June 6, 2026. This major corporate action is expected to have a high price impact as it confirms the historic split scheduled.
6/6/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Q2 2026 earnings release is scheduled.
6/2/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Costco Wholesale Corp (COST) · Earnings Release
Third quarter fiscal 2026 earnings release, estimated to have a moderate impact on the stock price upon release, scheduled.
5/28/2026, 12:00:00 AM